颗粒蛋白前体增强移植的人诱导多能干细胞源性大脑神经元的植入。
Progranulin enhances the engraftment of transplanted human iPS cell-derived cerebral neurons.
机构信息
Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Department of Neurosurgery, Kyushu University Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
出版信息
Stem Cells Transl Med. 2024 Nov 12;13(11):1113-1128. doi: 10.1093/stcltm/szae066.
Cerebral organoids (COs) in cell replacement therapy offer a viable approach to reconstructing neural circuits for individuals suffering from stroke or traumatic brain injuries. Successful transplantation relies on effective engraftment and neurite extension from the grafts. Earlier research has validated the effectiveness of delaying the transplantation procedure by 1 week. Here, we hypothesized that brain tissues 1 week following a traumatic brain injury possess a more favorable environment for cell transplantation when compared to immediately after injury. We performed a transcriptomic comparison to differentiate gene expression between these 2 temporal states. In controlled in vitro conditions, recombinant human progranulin (rhPGRN) bolstered the survival rate of dissociated neurons sourced from human induced pluripotent stem cell-derived COs (hiPSC-COs) under conditions of enhanced oxidative stress. This increase in viability was attributable to a reduction in apoptosis via Akt phosphorylation. In addition, rhPGRN pretreatment before in vivo transplantation experiments augmented the engraftment efficiency of hiPSC-COs considerably and facilitated neurite elongation along the host brain's corticospinal tracts. Subsequent histological assessments at 3 months post-transplantation revealed an elevated presence of graft-derived subcerebral projection neurons-crucial elements for reconstituting neural circuits-in the rhPGRN-treated group. These outcomes highlight the potential of PGRN as a neurotrophic factor suitable for incorporation into hiPSC-CO-based cell therapies.
脑类器官(COs)在细胞替代疗法中为中风或创伤性脑损伤患者重建神经网络提供了一种可行的方法。成功的移植依赖于移植物的有效植入和神经突延伸。早期的研究已经验证了将移植程序延迟 1 周的有效性。在这里,我们假设与损伤后立即相比,创伤性脑损伤后 1 周的脑组织更有利于细胞移植。我们进行了转录组比较,以区分这两种时间状态的基因表达。在受控的体外条件下,重组人颗粒蛋白前体(rhPGRN)增强了源自人诱导多能干细胞衍生的 CO(hiPSC-CO)的分离神经元在增强氧化应激条件下的存活率。这种活力的增加归因于 Akt 磷酸化导致的细胞凋亡减少。此外,在体内移植实验之前进行 rhPGRN 预处理显著提高了 hiPSC-CO 的植入效率,并促进了沿着宿主大脑皮质脊髓束的神经突伸长。移植后 3 个月的后续组织学评估显示,rhPGRN 治疗组中移植源性皮质下投射神经元的存在明显增加 - 这是重建神经网络的关键因素。这些结果突出了 PGRN 作为一种神经营养因子的潜力,适合纳入基于 hiPSC-CO 的细胞疗法。